CALGARY, AB (August 13, 2020) — Sundial Growers Inc. (NASDAQ: SNDL) (“Sundial” or the “Company”) reported its financial and operational results for the second quarter ended June 30, 2020. All financial information in this press release is reported in millions of Canadian dollars, unless otherwise indicated. All references to cannabis operations refer to the continuing operations of the Company. With the disposition of Bridge Farm on June 5, 2020, the ornamental flower operations have been represented as discontinued operations.
SECOND QUARTER 2020 FINANCIAL AND OPERATIONAL HIGHLIGHTS
• Net cannabis revenue for the second quarter of 2020 was $20.2 million, an increase of 44% over the first quarter of 2020
• Branded product average gross selling price for the quarter increased by 11% to $5.67 per gram equivalent from $5.11 per gram equivalent in the previous quarter
• Combined Sales, Marketing, General and Administration costs from cannabis operations decreased by 33% over the previous quarter to $8.3 million from $12.4 million
• Branded net cannabis sales increased to 69% of total cannabis sales from 54% in the previous quarter
• Dried bulk cannabis cost of goods sold per gram was $1.34 in the second quarter as compared to $1.21 in the previous quarter
• Net loss from cannabis operations was $31.6 million in the second quarter; adjusted EBITDA loss from cannabis operations decreased by 67% over the previous quarter to $3.9 million from $11.6 million
• Supply chain capabilities were improved with On Time In Full (OTIF) product delivery metrics above 90%
• An extensive financial restructuring was executed resulting in reduced leverage and improved liquidity, including the sale of the Bridge Farm Group for $90 million
• An inventory impairment provision of $13.4 million was recorded on dried cannabis and cannabis extracts
“August 1 marks Sundial’s one-year anniversary as a public company. In this limited timeframe, our team has executed on delivering branded product offerings to customers and captured market share with a narrow focus in the inhalables market,” said Zach George, Chief Executive Officer of Sundial. “While we are pleased to be one of a small group of Canadian LP’s able to post quarterly revenues greater than $20 million, we remain focused on the intense competitive landscape and the need to gain greater scale to reach sustainable profitability. We have made good progress in streamlining our business over the past six months, having eliminated non-core initiatives, reduced costs, and improved operating efficiencies. During this time, we also added new product offerings and reinforced our reputation as a high-quality cannabis producer. We still have significant work to do as we look to deliver on innovation, improve capacity utilization, and reduce our cost of goods sold. These initiatives, along with continued strong consumer demand and increased sales levels to date in 2020, should position us well for the balance of the year.”
“While the COVID-19 pandemic continues to bring many challenges, we are grateful for the dedication and commitment our employees have shown,” added Mr. George. “Our employees’ health and safety continue to be the priority for Sundial and we continue to focus on our stringent prevention measures to limit the potential spread of the virus within our organization.”
The Company continues to monitor daily developments in the COVID-19 pandemic and actions taken by the government authorities. In accordance with the guidance of provincial and federal health officials to limit the risk and transmission of COVID-19, Sundial has implemented mandatory self-quarantine policies, travel restrictions, enhanced cleaning and sanitation processes and frequency, and social distancing measures. Sundial believes that it can maintain safe operations with these pandemic-related procedures and protocols in place. The Company did not experience a material impact on its production and processing activities in the second quarter related to COVID-19.
STRATEGIC AND ORGANIZATIONAL UPDATE
Sundial’s overall strategy is to build sustainable, long-term shareholder value by reducing leverage, improving liquidity and cost of capital while optimizing the capacity and capabilities of its production facilities.
To achieve this, Sundial will continue its focus on:
• Meeting evolving consumer preferences by being a consumer-centric organization with data-driven consumer insights and analytics
• Delivering industry-leading, best-in-class brands and products with a focus on inhalables and potency levels of THC greater than 18%
• Innovating on genetics, products and processes and continuing to invest in the Company’s brands
• Driving quality in all aspects of the Company’s operation and delivering products that consumers want, when and where they want them
• Continuing to improve cost discipline and maintaining a variable cost structure and flexible production capacity to adapt to industry dynamics
Sundial expects 2020 to be a transition year as the Company has reset its strategic focus, streamlined its organizational structure, and implemented a comprehensive operational and supply chain productivity optimization program.
STRATEGIC ALTERNATIVES REVIEW INITIATED
Following a review of its business, Sundial recently initiated and continues a process to explore strategic alternatives focused on maximizing shareholder value. Sundial’s board of directors (“Board”) has authorized management and its external advisors to consider a broader range of strategic alternatives, including a potential sale of the Company, merger or other business combination, investments in other Canadian cannabis companies, including dispensaries and other retail outlets, dispositions of discrete brands and related assets, optimizing its assets, including the potential sale of its Rocky View and Merritt facilities, selling limited quantities of inventory at or below cost and entering into long-term supply agreements with other licensed producers, licensing or other strategic transactions involving the Company, or any combination of the foregoing. Sundial has engaged a financial advisor to assist with these efforts.
There can be no assurance that the exploration of strategic alternatives will result in any transaction or specific course of action. The Company has not set a timetable for the conclusion of its review of strategic alternatives and does not intend to disclose developments with respect to the exploration of strategic alternatives unless and until its Board has approved a specific transaction or course of action or the Company has otherwise determined that further disclosure is appropriate or required by law.
SECOND QUARTER 2020 KEY FINANCIAL METRICS
|Gross Revenue||Net Revenue||Gross Margin (1)||Net Loss||Adj. EBITDA|
|% Change Q1 2020||47%||44%||473%||18%||67%|
|% Change Q2 2019||20%||5%||-68%||-156%||-757%|
SECOND QUARTER 2020 BUSINESS & OPERATIONAL HIGHLIGHTS
Gross margin from cannabis operations before inventory impairment and fair value adjustments for the three months ended June 30, 2020 was $2.9 million compared to $0.5 million for the three months ended March 31, 2020. The increase of $2.4 million was mainly due to increased revenue, efficiency gains as realized by decreased cost of goods sold and incremental product mix.
GROSS SELLING PRICE
Average gross selling price per gram equivalent of branded products was $5.67 per gram in the second quarter of 2020, including net provisions, compared to $5.11 per gram in the prior quarter. The change in average gross selling price was primarily due to an increase in vape sales. Average gross selling prices for unbranded flower in the second quarter were $2.82 per gram up from $2.74 per gram in the previous quarter despite competitive pressures in the wholesale market as a result of industry-wide increased inventory levels.
REVENUE BY FORMATS
Sundial remains focused on delivering industry-leading, best-in-class products with a focus on inhalable products, including flower, pre-rolls and vape cartridges. Gross revenue from vape cartridge sales was $6.3 million in the second quarter of 2020 representing a 44% increase from the previous quarter. Sundial continues to build on strong consumer adoption with its vape portfolio and continues to diversify its product mix with plans for the addition of solventless extracts by the fourth quarter of this year.
The Company sold 5,997 kilogram equivalents of cannabis in the second quarter of 2020, a 35% increase over the previous quarter sales of 4,437 kilogram equivalents.
NET BRANDED SALES
The Company has seen commercial success in the second quarter of 2020 with a significant increase of branded sales. This success can be attributed to its strong recreational launch in Quebec, supply chain optimization and continued market share penetration within the inhalable products segment nationally. Branded net cannabis sales in the second quarter of 2020 were $14.0 million compared to $7.6 million in the first quarter of 2020, an increase of 84%, supporting Sundial’s strategy to focus on increased sales to Provincial Boards.
COST OF GOODS SOLD PER GRAM EQUIVALENT
Cost of goods sold per gram of bulk dried cannabis was $1.34 in the second quarter, an increase of 11% over $1.21 per gram in the prior quarter. This increase is attributable to a decrease in production capacity utilization and consequent allocation of manufacturing overhead over fewer grams. Total cost of goods sold per gram including packaging, shipment and fulfillment costs for the three months ended June 30, 2020 was $2.89 compared to $3.04 for the previous quarter. The decrease of $0.15 per gram was due to improved production efficiencies. Continuously reducing this metric will be a key focus for the Company moving forward.
GENERAL AND ADMINISTRATIVE & SALES AND MARKETING EXPENSES
General and administrative costs related to cannabis operations were reduced by 27% from $10.6 million to $7.7 million in the second quarter of 2020 when compared to the prior quarter. The reduction in our workforce to adjust to market conditions and a focused review of all spending resulted in this decline. Sales and marketing costs (agency and direct costs) were decreased by 72% from $1.8 million to $0.5 million in the second quarter of 2020 when compared to the prior quarter as many of these costs were deferred. The Company expects a significant increase in sales and marketing expenditures in future quarters.
Net loss from cannabis operations for the three months ended June 30, 2020 was $31.6 million compared to a net loss of $38.4 million for three months ended March 31, 2020. The decreased loss of $6.8 million was primarily due to improvement on loss from operations, partially offset by provisions against the Company’s inventory and biological assets to reflect current and rapidly evolving market conditions.
Adjusted EBITDA from cannabis operations was a loss of $3.9 million for the three months ended June 30, 2020 compared to a loss of $11.6 million for the three months ended March 31, 2020. The decreased loss was primarily due to the following:
• Increase in net revenue
• Decrease in general and administrative expenses
• Decrease in sales and marketing due to a decrease in general marketing activities
• Decrease in research and development
The decreased loss was partially offset by the increase in cost of sales due to extraction costs and an increase in kilogram equivalents sold.
LIQUIDITY AND CAPITAL RESOURCES
• Sundial secured an amendment to its $79.3 million syndicated credit agreement deferring all material financial covenants other than maintaining a minimum cash balance of $2.5 million and securing additional equity financing of US$10 million on or prior to December 1, 2020.
• Concurrent with the disposition of the Bridge Farm Group, $45 million of Sundial’s term debt facility was extinguished with the remaining $73.2 million converted into non-interest bearing convertible notes.
• Sundial issued US$18 million in senior unsecured subordinated convertible notes with accompanying warrants to institutional investors for proceeds, net of original issue discount, placement agent’s fees and other expenses, of US$13.3 million. Subsequent to June 30, US$6,900,00 of the convertible notes were converted into 14,100,00 common shares.
• Subsequent to the quarter end, Sundial has filed a registration statement for a mixed shelf prospectus allowing it to issue common shares in an amount up to US$100 million at its discretion, and intends to establish an At-the-Market (“ATM”) equity program covering issuances of up to US$50 million.
Certain financial measures in this news release, including adjusted EBITDA, working capital and gross margin before fair value adjustments are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for measures of performance prepared in accordance with IFRS.
Adjusted EBITDA is a non-IFRS measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts and others to aid in understanding and evaluating the Company’s operating results in a similar manner to its management team. Adjusted EBITDA is defined as net income (loss) before finance costs, depreciation and amortization, accretion expense, income tax recovery and excluding change in fair value of biological assets, change in fair value realized through inventory, unrealized foreign exchange gains or losses, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment and certain one-time non-operating expenses, as determined by management.
|Q2 2020||Q1 2020||% Change||Q2 2019||% Change|
|Net loss from continuing operations||(31,560)||(38,390)||18%||(12,350)||-156%|
|Loss on financial obligation||-||-||0%||725||-100%|
|Depreciation and amortization||1,277||657||94%||148||763%|
|Change in fair value of biological assets||1,756||(6,415)||127%||(12,174)||114%|
|Change in fair value realized through inventory||6,213||9,692||-36%||1,769||251%|
|Unrealized foreign exchange (gain) loss||583||(1,769)||133%||555||5%|
|Loss on disposition of PP&E||122||(610)||120%||(15)||913%|
|Cost of sales non-cash component (1)||1,549||780||99%||-||0%|
|Inventory obsolescence and impairment||10,026||7,715||30%||-||0%|
|Transaction costs (2)||1,297||1,101||18%||-||0%|
|Adjusted EBITDA from continuing operations||(3,898)||(11,643)||67%||(455)||-757%|
Sundial will host a conference call and webcast at 10:30 a.m. EDT (8:30 a.m. MDT) on Friday, August 14, 2020. A current investor presentation will be available on http://sndlgroup.com/investors at that time.
CONFERENCE CALL ACCESS
Callers may access the conference call via the following phone numbers: Canada/USA Toll Free: 1-800-319-4610 International Toll: +1-604-638-5340 UK Toll Free: 0808-101-2791 Callers should dial in 5-10 minutes prior to the scheduled start time.
To access the live webcast of the call, please visit the following link: http://services.choruscall.ca/links/sundialgrowers20200814.html
A telephone replay will be available for one month. To access the replay dial: Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010 When prompted, enter Replay Access Code: 5053 # The webcast archive will be available for three months via the link provided above.
Sundial Growers Inc. (Nasdaq: SNDL) (“Sundial”) today announced that it will participate in a virtual event as part of Alliance Global Partners’ Consumer Cannabis Conference.Read More
CALGARY, AB, Aug. 18, 2020 - Sundial Growers Inc. (NASDAQ: SNDL) ("Sundial" or the "Company") announced today that it has closed a best efforts underwritten registered offering of 25,820,000 Series A Units, each consisting of one common share and one Series A Warrant to purchase one common share and 14,280,000 Series B Units (and together with the Series B Units, the “Units”), each consisting of one pre-funded Series B Warrant (together with the Series A Warrants, the “warrants”) to purchase one common share and one Series A Warrant to purchase one common shareRead More
Sundial Growers Inc. (NASDAQ: SNDL) ("Sundial" or the "Company") announced today that it has priced a best efforts underwritten registered offering of 25,820,000 Series A Units.Read More